Article
Otorhinolaryngology
Kevin K. Zarrabi, Thomas J. Galloway, Douglas B. Flieder, Sameera S. Kumar, Julia Judd, Jessica R. Bauman
Summary: In this study, a novel assay for plasma circulating tumor HPV DNA was used as a potential tool for monitoring the treatment of HPV-mediated oropharyngeal carcinoma.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2022)
Article
Oncology
Matthew C. Ward, Jacob A. Miller, Gary V. J. Walker, Benjamin A. Moeller, Shlomo Koyfman, Chirag Shah
Summary: This study investigated a novel blood test for monitoring recurrence of HPV-driven oropharynx cancer. The test was found to be relatively expensive but had the potential to reduce unnecessary imaging. It may be cost-saving or cost-effective if future data demonstrate small improvements in quality or quantity of life and if the testing frequency can be reduced.
Article
Chemistry, Analytical
Binny Jaradi, Tulika Das, Kevin M. Koo
Summary: Infection with oncogenic strains of HPV can lead to malignant progression and tumorigenesis. In this study, a novel thermostable enzyme chemistries-based assay was developed for rapid clinical HPV screening. The use of thermostable enzymes provided faster cHPV-DNA extraction and amplification, resulting in improved overall assay time and achieving excellent sensitivity and specificity in human plasma specimens.
ANALYTICAL CHEMISTRY
(2023)
Article
Oncology
Susanne Flach, Karen Howarth, Sophie Hackinger, Christodoulos Pipinikas, Pete Ellis, Kirsten McLay, Giovanni Marsico, Tim Forshew, Christoph Walz, Christoph A. Reichel, Olivier Gires, Martin Canis, Philipp Baumeister
Summary: This study demonstrates the potential of ctDNA as a biomarker for detecting minimal residual disease and recurrence in HNSCC and shows the feasibility of personalized ctDNA assays for disease detection prior to clinical recurrence.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Connor J. O'Boyle, Giulia Siravegna, Shohreh Varmeh, Natalia Queenan, Alexa Michel, Kim Chang Sing Pang, Jarrod Stein, Julia C. Thierauf, Peter M. Sadow, William C. Faquin, Wei Wang, Daniel G. Deschler, Kevin S. Emerick, Mark A. Varvares, Jong C. Park, John R. Clark, Annie W. Chan, Paul M. Busse, Ryan B. Corcoran, Lori J. Wirth, Derrick T. Lin, A. John Iafrate, Jeremy D. Richmon, Daniel L. Faden
Summary: POD 1 ctHPVDNA levels are associated with the risk of residual disease in patients with HPV+OPSCC undergoing curative intent surgery and could be used as a personalized biomarker for selecting adjuvant treatment in the future.
Article
Cell Biology
Sara Bonlokke, Magnus Stougaard, Boe Sandahl Sorensen, Berit Bargum Booth, Estrid Hogdall, Gitte-Bettina Nyvang, Jacob Christian Lindegaard, Jan Blaakaer, Jesper Bertelsen, Katrine Fuglsang, Mikael Lenz Strube, Suzan Lenz, Torben Steiniche
Summary: Circulating cell-free HPV DNA (ccfHPV DNA) can serve as a marker for cervical cancer. This study used digital droplet PCR (ddPCR) to detect and quantify ccfHPV DNA in plasma from patients with HPV16- or HPV18-associated cervical cancer. The results showed that ccfHPV DNA may not be useful for early detection of cervical cancer, but it can be a promising tool for establishing tumor burden and monitoring the disease in advanced stage cervical cancer patients.
Article
Medicine, Research & Experimental
Weiwei Feng, Nan Jia, Haining Jiao, Jun Chen, Yan Chen, Yueru Zhang, Menghan Zhu, Chongying Zhu, Lifei Shen, Wenqing Long
Summary: The study demonstrated the effectiveness and stability of personalized ctDNA detection in high-risk EC patients for monitoring and predicting tumor recurrence. CtDNA tracking in post-operative plasma is valuable in predicting tumor relapse.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Review
Oncology
Agnieszka M. Mazurek, Tomasz W. Rutkowski
Summary: This article discusses the clinical benefits of the molecular response (MR) obtained through the assessment of circulating tumor-related HPV DNA (ctHPV) in liquid biopsies (LBs) for patients with HPV-related oropharyngeal cancer (OPC). MR assessment can help evaluate the intensity of ongoing treatments and assess residual disease at the end of therapy. It can also hasten the early detection of disease progression.
Article
Oncology
Mariateresa Casarotto, Valentina Lupato, Giorgio Giurato, Roberto Guerrieri, Sandro Sulfaro, Annamaria Salvati, Elisa D'Angelo, Carlo Furlan, Anna Menegaldo, Lorena Baboci, Barbara Montico, Irene Turturici, Riccardo Dolcetti, Salvatore Romeo, Vittorio Baggio, Stefania Corrado, Gianluca Businello, Maria Guido, Alessandro Weisz, Vittorio Giacomarra, Giovanni Franchin, Agostino Steffan, Luca Sigalotti, Emanuela Vaccher, Paolo Boscolo-Rizzo, Polesel Jerry, Giuseppe Fanetti, Elisabetta Fratta
Summary: This study evaluated the prognostic value of LINE-1 methylation level in oropharyngeal squamous cell carcinoma (OPSCC) patients. The results indicated that LINE-1 hypomethylation was associated with poor prognosis. The study also examined the relationship between LINE-1 methylation status and p53 protein expression as well as genome-wide/gene-specific DNA methylation.
CLINICAL EPIGENETICS
(2022)
Article
Medical Laboratory Technology
Guigao Lin, Jinming Li
Summary: Human papillomavirus (HPV) infections are the main cause of various types of cancers, and circulating HPV DNA (cHPV-DNA) is a potential biomarker for the management of HPV-driven malignancies. There have been advancements in techniques for analyzing cHPV-DNA for the detection, characterization, and monitoring of HPV-associated cancers. Clinical trials assessing the clinical utility of cHPV-DNA can confirm its potential for screening, diagnosis, and treatment of HPV-related malignancies.
CLINICA CHIMICA ACTA
(2023)
Article
Oncology
Jeanne Tie, Joshua D. Cohen, Serigne N. Lo, Yuxuan Wang, Lu Li, Michael Christie, Margaret Lee, Rachel Wong, Suzanne Kosmider, Iain Skinner, Hui Li Wong, Belinda Lee, Matthew E. Burge, Desmond Yip, Christos S. Karapetis, Timothy J. Price, Niall C. Tebbutt, Andrew M. Haydon, Janine Ptak, Mary J. Schaeffer, Natalie Silliman, Lisa Dobbyn, Maria Popoli, Cristian Tomasetti, Nickolas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein, Peter Gibbs
Summary: Studies have shown that postoperative ctDNA analysis is prognostically significant in nonmetastatic CRC patients, with higher predictive accuracy for recurrence compared to clinicopathologic risk factors, and increasing mutant allele frequency (MAF) further stratifying recurrence risk.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Review
Oncology
Mehmet Gunduz, Esra Gunduz, Shunji Tamagawa, Keisuke Enomoto, Muneki Hotomi
Summary: Although progress has been made in understanding cancer stem cells, particularly in oropharyngeal cancer, much remains unknown. These stem cells play roles in tumor invasion, metastasis, drug resistance, and recurrence, but there are still many unanswered questions.
Editorial Material
Oncology
Joanne Soo, Michael C. Jin, Beth M. Beadle, F. Christopher Holsinger, Andrey Finegersh
Summary: This study reveals that measuring the genetic components of human papillomavirus-related throat cancer after surgery can help predict the effectiveness of treatment.
Review
Medicine, General & Internal
Eriseld Krasniqi, Maddalena Barba, Aldo Venuti, Laura Pizzuti, Federico Cappuzzo, Lorenza Landi, Silvia Carpano, Paolo Marchetti, Alice Villa, Enrico Vizza, Greta Giuliano, Marco Mazzotta, Daniele Marinelli, Sandra Gnignera, Cristina Vincenzoni, Vincenzo Stranges, Domenico Sergi, Antonio Giordano, Federica Tomao, Marcello Maugeri-Sacca, Giuseppe Sanguineti, Francesca Sofia Di Lisa, Silverio Tomao, Gennaro Ciliberto, Patrizia Vici
Summary: HPVs are linked to cervical and oropharyngeal cancers, and circulating HPV DNA serves as a potential biomarker for clinical management. Specific and minimally invasive tests can enable early detection and treatment monitoring, with innovative techniques enhancing the detection rate of serum HPV DNA.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Oncology
Mira Shoukry, Sacha Broccard, Jamie Kaplan, Emmanuel Gabriel
Summary: As breast cancer diagnoses continue to increase globally, exploring the role of liquid biopsies and circulating tumor DNA (ctDNA) in diagnosis and surveillance becomes increasingly important. CtDNA is emerging as a potential biomarker for breast cancer, offering personalized and effective treatment approaches.
Meeting Abstract
Oncology
G. P. Gupta, S. Kumar, D. Marron, R. J. Amdur, D. N. Hayes, J. Weiss, J. Grilley-Olson, A. Zanation, T. Hackman, J. P. Zevallos, S. Patel, M. Weissler, J. S. Parker, W. M. Mendenhall, B. S. Chera
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2018)
Article
Medicine, Research & Experimental
Marni B. Siegel, Xiaping He, Katherine A. Hoadley, Alan Hoyle, Julia B. Pearce, Amy L. Garrett, Sunil Kumar, Vincent J. Moylan, Claudia M. Brady, Amanda E. D. Van Swearingen, David Marron, Gaorav P. Gupta, Leigh B. Thorne, Niamh Kieran, Chad Livasy, Elaine R. Mardis, Joel S. Parker, Mengjie Chen, Carey K. Anders, Lisa A. Carey, Charles M. Perou
JOURNAL OF CLINICAL INVESTIGATION
(2018)
Article
Microbiology
Tejaswani Saragadam, Sunil Kumar, Narayan S. Punekar
Article
Oncology
Bhishamjit S. Chera, Sunil Kumar, Brian T. Beaty, David Marron, Stuart Jefferys, Rebecca Green, Emily C. Goldman, Robert Amdur, Nathan Sheets, Roi Dagan, D. Neil Hayes, Jared Weiss, Juneko E. Grilley-Olson, Adam Zanation, Trevor Hackman, Jeffrey M. Blumberg, Samip Patel, Mark Weissler, Xianming M. Tan, Joel S. Parker, William Mendenhall, Gaorav P. Gupta
CLINICAL CANCER RESEARCH
(2019)
Meeting Abstract
Oncology
Sunil Kumar, Bhishamjit S. Chera, Brian Beaty, David Marron, Stuart Jefferys, Robert Amdur, Nathan Sheets, Roi Dagan, David N. Hayes, Jared Weiss, Juneko E. Grilley-Olson, Adam M. Zanation, Trevor Hackman, Jeffrey Blumberg, Samip Patel, Mark Christian Weissler, Joel S. Parker, Xianming Tan, William M. Mendenhall, Gaorav Gupta
JOURNAL OF CLINICAL ONCOLOGY
(2019)
Meeting Abstract
Oncology
G. P. Gupta, S. Kumar, C. Shen, R. J. Amdur, R. Dagan, J. Weiss, J. Grilley-Olson, A. Zanation, T. Hackman, J. Blumberg, S. Patel, B. Thorp, M. Weissler, N. C. Sheets, W. M. Mendenhall, B. S. Chera
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2019)
Meeting Abstract
Oncology
D. M. Routman, B. S. Chera, K. R. Jethwa, K. Van Abel, S. Kumar, T. A. DeWees, J. J. Garcia, D. L. Price, J. L. Kasperbauer, N. N. Laack, M. A. Neben-Wittich, Y. Garces, A. V. Chintakuntlawar, K. A. Price, M. C. Liu, R. L. Foote, E. J. Moore, G. P. Gupta, D. J. Ma
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2019)
Article
Pathology
Margaret L. Gulley, Sandra Elmore, Gaorav P. Gupta, Sunil Kumar, Matthew Egleston, Ian J. Hoskins, Aaron Garnett
JOURNAL OF MOLECULAR DIAGNOSTICS
(2020)
Article
Medicine, Research & Experimental
Sm N. Udden, Qian Wang, Sunil Kumar, Venkat S. Malladi, Shwu-Yuan Wu, Shuguang Wei, Bruce A. Posner, Sophie Geboers, Noelle S. Williams, Yulun Liu, Jayesh K. Sharma, Ram S. Mani, Srinivas Malladi, Karla Parra, Mia Hofstad, Ganesh Raj, Jose M. Larios, Reshma Jagsi, Max S. Wicha, Ben Ho Park, Gaorav P. Gupta, Arul M. Chinnaiyan, Cheng-Ming Chiang, Prasanna G. Alluri
Summary: High-throughput screening of FDA-approved drugs identified BET inhibitor OTX015 as a top suppressor of ESR1 mutant cell growth, showing superior efficacy compared to fulvestrant. When combined with CDK4/6 inhibitor abemaciclib, OTX015 induced more potent tumor regression than current standard-of-care treatment.
Article
Medicine, General & Internal
Alicia Gunning, Sunil Kumar, Cassin Kimmel Williams, Barry M. Berger, Stephen P. Naber, Piyush B. Gupta, Catherine Del Vecchio Fitz, Charlotte Kuperwasser
Summary: The NavDx blood test is a reliable method for detecting and monitoring HPV-driven cancers by analyzing tumor tissue modified viral-HPV DNA. It has been clinically validated and integrated into clinical practice by over 1000 healthcare providers at over 400 medical sites in the US. The test is accredited by the College of American Pathologists and the New York State Department of Health and has demonstrated high sensitivity and specificity.
Article
Oncology
Ryan M. Murphy, Jason Tasoulas, Alessandro Porrello, Miranda B. Carper, Yi-Hsuan Tsai, Alisha R. Coffey, Sunil Kumar, Peter YF. Zeng, Travis P. Schrank, Bentley R. Midkiff, Stephanie Cohen, Ashley H. Salazar, Michele C. Hayward, D. Neil Hayes, Andrew Olshan, Gaorav P. Gupta, Anthony C. Nichols, Wendell G. Yarbrough, Chad V. Pecot, Antonio L. Amelio
Summary: Over 70% of oropharyngeal head and neck squamous cell carcinoma (HNSC) cases in the United States are positive for human papillomavirus (HPV). This study identified robust expression of Synaptogyrin-3 (SYNGR3) gene in immune cells of HPV(+) squamous cancers and demonstrated that codetection of SYNGR3 and p16 by immunohistochemistry (IHC) can more reliably identify the low-risk subgroup of patients that may be appropriate for deescalation treatments.
CANCER RESEARCH COMMUNICATIONS
(2022)
Meeting Abstract
Oncology
A. E. Garda, K. R. Jethwa, D. M. Routman, S. Kumar, B. S. Chera, J. Viehman, H. Sandhyavenu, M. C. Liu, N. N. Laack, C. L. Hallemeier, R. L. Foote, I. A. Petersen, M. G. Haddock, G. P. Gupta, D. J. Ma
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2020)
Meeting Abstract
Oncology
S. Kumar, D. Lindsay, B. Chen, A. L. Garrett, X. M. Tan, C. K. Anders, L. A. Carey, G. P. Gupta
Article
Oncology
Sunil Kumar, Daniel Lindsay, Q. Brent Chen, Amy L. Garrett, Xianming M. Tan, Carey K. Anders, Lisa A. Carey, Gaorav P. Gupta